Compare Incyte Corporation (INCY) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tapestry, Inc. — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while Tapestry, Inc. trades at $141.64 (market cap $28.51B). The key difference: Tapestry, Inc. is the larger of the two by market cap, and Tapestry, Inc. pays a 1.13% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TPR | |
|---|---|---|
Market Cap | $23.11B | $28.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $160.49 |
52-Week Low | $67.38 | $95.69 |
Enterprise Value | $19.13B | $31.37B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
TPR trades at $140.45, down 0.71% on the day, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a 76.18% gross margin and 55.74% ROE, though net income margin fell to 8.44% in 2025. Recent quarters have consistently beaten EPS estimates, and analyst consensus is strongly bullish with a $183.88 price target. Cash flow trends are volatile, with 2025 showing a net outflow of $5.02B due to financing activities.
Outlook remains positive driven by earnings beats and digital growth, but high valuation ratios (P/E 43.13) and debt levels pose risks. The stock offers 31% upside to consensus target, supported by institutional buy ratings and strong brand momentum in luxury retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
